133 related articles for article (PubMed ID: 27389555)
1. Comparison of Antibodies for Immunohistochemistry-based Detection of HER3 in Breast Cancer.
Luhtala S; Staff S; Barok M; Tanner M; Isola J
Appl Immunohistochem Mol Morphol; 2018 Mar; 26(3):212-219. PubMed ID: 27389555
[TBL] [Abstract][Full Text] [Related]
2. Droplet digital polymerase chain reaction detection of HER2 amplification in formalin fixed paraffin embedded breast and gastric carcinoma samples.
Zhu Y; Lu D; Lira ME; Xu Q; Du Y; Xiong J; Mao M; Chung HC; Zheng G
Exp Mol Pathol; 2016 Apr; 100(2):287-93. PubMed ID: 26626802
[TBL] [Abstract][Full Text] [Related]
3. Development and evaluation of a novel RT-qPCR based test for the quantification of HER2 gene expression in breast cancer.
El Hadi H; Abdellaoui-Maane I; Kottwitz D; El Amrani M; Bouchoutrouch N; Qmichou Z; Karkouri M; ElAttar H; Errihani H; Fernandez PL; Bakri Y; Sefrioui H; Moumen A
Gene; 2017 Mar; 605():114-122. PubMed ID: 28039034
[TBL] [Abstract][Full Text] [Related]
4. Clinicopathological and prognostic correlations of HER3 expression and its degradation regulators, NEDD4-1 and NRDP1, in primary breast cancer.
Luhtala S; Staff S; Kallioniemi A; Tanner M; Isola J
BMC Cancer; 2018 Oct; 18(1):1045. PubMed ID: 30367623
[TBL] [Abstract][Full Text] [Related]
5. HER2 immunohistochemical assessment with A0485 polyclonal antibody: is it time to refine the scoring criteria for the "2+" category?
Pennacchia I; Vecchio FM; Carbone A; Arena V
Appl Immunohistochem Mol Morphol; 2015 Jan; 23(1):31-5. PubMed ID: 25356940
[TBL] [Abstract][Full Text] [Related]
6. Validation and comparison of anti-αvβ3 and anti-αvβ5 rabbit monoclonal versus murine monoclonal antibodies in four different tumor entities.
Böger C; Kalthoff H; Goodman SL; Röcken C
Appl Immunohistochem Mol Morphol; 2013 Dec; 21(6):553-60. PubMed ID: 23455183
[TBL] [Abstract][Full Text] [Related]
7. Sensitivity and specificity of monoclonal and polyclonal immunohistochemical staining for West Nile virus in various organs from American crows (Corvus brachyrhynchos).
Smedley RC; Patterson JS; Miller R; Massey JP; Wise AG; Maes RK; Wu P; Kaneene JB; Kiupel M
BMC Infect Dis; 2007 May; 7():49. PubMed ID: 17537263
[TBL] [Abstract][Full Text] [Related]
8. A central role for HER3 in HER2-amplified breast cancer: implications for targeted therapy.
Lee-Hoeflich ST; Crocker L; Yao E; Pham T; Munroe X; Hoeflich KP; Sliwkowski MX; Stern HM
Cancer Res; 2008 Jul; 68(14):5878-87. PubMed ID: 18632642
[TBL] [Abstract][Full Text] [Related]
9. Characterization of anti-TIMP-1 monoclonal antibodies for immunohistochemical localization in formalin-fixed, paraffin-embedded tissue.
Sorensen IV; Fenger C; Winther H; Foged NT; Lademann U; Brünner N; Usher PA
J Histochem Cytochem; 2006 Oct; 54(10):1075-86. PubMed ID: 16517973
[TBL] [Abstract][Full Text] [Related]
10. Analysis of ERBB2 and TOP2A gene status using fluorescence in situ hybridization versus immunohistochemistry in localized breast cancer.
Bouchalová K; Trojanec R; Kolár Z; Cwiertka K; Cernáková I; Mihál V; Hajdúch M
Neoplasma; 2006; 53(5):393-401. PubMed ID: 17013533
[TBL] [Abstract][Full Text] [Related]
11. Comparison of central laboratory assessments of ER, PR, HER2, and Ki67 by IHC/FISH and the corresponding mRNAs (ESR1, PGR, ERBB2, and MKi67) by RT-qPCR on an automated, broadly deployed diagnostic platform.
Wu NC; Wong W; Ho KE; Chu VC; Rizo A; Davenport S; Kelly D; Makar R; Jassem J; Duchnowska R; Biernat W; Radecka B; Fujita T; Klein JL; Stonecypher M; Ohta S; Juhl H; Weidler JM; Bates M; Press MF
Breast Cancer Res Treat; 2018 Nov; 172(2):327-338. PubMed ID: 30120700
[TBL] [Abstract][Full Text] [Related]
12. Quantitation of p95HER2 in paraffin sections by using a p95-specific antibody and correlation with outcome in a cohort of trastuzumab-treated breast cancer patients.
Sperinde J; Jin X; Banerjee J; Penuel E; Saha A; Diedrich G; Huang W; Leitzel K; Weidler J; Ali SM; Fuchs EM; Singer CF; Köstler WJ; Bates M; Parry G; Winslow J; Lipton A
Clin Cancer Res; 2010 Aug; 16(16):4226-35. PubMed ID: 20664024
[TBL] [Abstract][Full Text] [Related]
13. Analytic variability in immunohistochemistry biomarker studies.
Anagnostou VK; Welsh AW; Giltnane JM; Siddiqui S; Liceaga C; Gustavson M; Syrigos KN; Reiter JL; Rimm DL
Cancer Epidemiol Biomarkers Prev; 2010 Apr; 19(4):982-91. PubMed ID: 20332259
[TBL] [Abstract][Full Text] [Related]
14. A novel proximity assay for the detection of proteins and protein complexes: quantitation of HER1 and HER2 total protein expression and homodimerization in formalin-fixed, paraffin-embedded cell lines and breast cancer tissue.
Shi Y; Huang W; Tan Y; Jin X; Dua R; Penuel E; Mukherjee A; Sperinde J; Pannu H; Chenna A; DeFazio-Eli L; Pidaparthi S; Badal Y; Wallweber G; Chen L; Williams S; Tahir H; Larson J; Goodman L; Whitcomb J; Petropoulos C; Winslow J
Diagn Mol Pathol; 2009 Mar; 18(1):11-21. PubMed ID: 19214113
[TBL] [Abstract][Full Text] [Related]
15. HER2 evaluation using the novel rabbit monoclonal antibody SP3 and CISH in tissue microarrays of invasive breast carcinomas.
Ricardo SA; Milanezi F; Carvalho ST; Leitão DR; Schmitt FC
J Clin Pathol; 2007 Sep; 60(9):1001-5. PubMed ID: 17158643
[TBL] [Abstract][Full Text] [Related]
16. Assessment of a new anti-HER2 monoclonal antibody, SV2-61gamma: a best concordance with HER2 FISH.
Kitano Y; Umemura S; Ohbayashi H; Takenaga M; Osamura RY
Appl Immunohistochem Mol Morphol; 2007 Dec; 15(4):389-93. PubMed ID: 18091380
[TBL] [Abstract][Full Text] [Related]
17. Profiling signalling pathways in formalin-fixed and paraffin-embedded breast cancer tissues reveals cross-talk between EGFR, HER2, HER3 and uPAR.
Berg D; Wolff C; Malinowsky K; Tran K; Walch A; Bronger H; Schuster T; Höfler H; Becker KF
J Cell Physiol; 2012 Jan; 227(1):204-12. PubMed ID: 21391216
[TBL] [Abstract][Full Text] [Related]
18. HER 2 immunohistochemistry for breast cancer cell blocks can be used in the same way as that used for histological specimens.
Nishimura R; Okamoto N; Satou M; Kojima K; Tanaka S
Diagn Cytopathol; 2016 Apr; 44(4):274-9. PubMed ID: 26800514
[TBL] [Abstract][Full Text] [Related]
19. Validation of a fully automated HER2 staining kit in breast cancer.
Moelans CB; Kibbelaar RE; van den Heuvel MC; Castigliego D; de Weger RA; van Diest PJ
Cell Oncol; 2010; 32(1-2):149-55. PubMed ID: 20203372
[TBL] [Abstract][Full Text] [Related]
20. Human epidermal growth factor receptor 2 amplification detection by droplet digital polymerase chain reaction in formalin-fixed paraffin-embedded breast and gastric cancer samples.
Wang X; Wu Y; Song X; Sun C; Wu C; Feng H
J Cancer Res Ther; 2017; 13(4):730-734. PubMed ID: 28901323
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
